Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer
| Autor: | Dalila Satta, Leila Beddar, Feriel Sellam, Amira Lyna Rouibah, Anissa Nini, Ali Boumegoura, Houda Boufendi, Asma Temim, Mohamed Lahmadi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Lung Neoplasms Population Adenocarcinoma medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Non-small cell lung cancer Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor medicine Humans Epidermal growth factor receptor education Lung cancer Aged Retrospective Studies Aged 80 and over education.field_of_study Mutation biology business.industry Incidence (epidemiology) Retrospective cohort study General Medicine Middle Aged medicine.disease ErbB Receptors 030104 developmental biology EGFR gene Algeria 030220 oncology & carcinogenesis biology.protein Female business Tyrosine kinase Research Article |
| Zdroj: | Asian Pacific Journal of Cancer Prevention : APJCP |
| ISSN: | 2476-762X |
| Popis: | Background and objective Epidermal growth factor receptor (EGFR) mutation status is used as a predictive biomarker for the tyrosine kinase inhibitors therapy in non-small cell lung cancer (NSCLC). The incidence of EGFR mutations appears to vary according to ethnic and geographical backgrounds. This retrospective study aimed to investigate the EGFR mutation status in Algerian NSCLC patients and its association with clinicopathological features. Methods We examined the presence of EGFR mutations (Exons 19-21) in 58 unselected NSCLC samples using PCR followed by direct sequencing. Results The present study included 53 (91.4%) men and 5 (8.6%) women, with a median age of 59 (ranging from 44 to 94 years old). EGFR mutations were detected in 23 patients, with an overall rate of 39.6%. There were 21 (91.3%) cases with the exon-21 L585R single mutation and two (8.7%) with dual mutations of exon-19 deletions and L585R. EGFR mutations were more frequently found in patients with confirmed adenocarcinoma (14/27, 51.8%) than in non-adenomatous NCSCL subtypes (3/14, 21.4%; p=0.03). Furthermore, early stages of the disease were significantly associated with a higher rate of EGFR mutations (14/27, 51.8%) compared with those at advanced stage (5/21, 23.8%; p=0.02). There were no significant differences in EGFR mutation frequency by age, gender, or smoking status. Conclusion We found that Algerian NSCLC patients exhibited a high rate of EGFR mutations, which was quite similar to that in Asians population rather than Caucasian patients. Thus, TKI-based treatments may be more beneficial for Algerian patients with NSCLC. Further studies using a large number of patients are required to confirm our preliminary findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|